Education
- 2003: PhD in Gynaecology and Obstetrics, University of Parma, Italy
- 1999: Specialisation in Gynaecology and Obstetrics cum laude, Università Cattolica del Sacro Cuore, Rome, Italy
- 1995: Degree in Medicine and Surgery with honours, Università Cattolica del Sacro Cuore, Rome, Italy
Academic Appointments
- 2024 – present: Full Professor, Humanitas University, Rozzano, Italy
- 2020 – 2023: Associate Professor, Università Cattolica del Sacro Cuore, Rome, Italy
- 2011 – 2018: Head, Medical Treatment of Gynaecological Neoplasms and Clinical Trials, Gynaecological Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy (come attività didattico-clinica integrata, se prevista nell’università, altrimenti spostabile in Other)
Other
- 2019 – 2023: Head, Clinical Research Development Unit, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
- 2007 – 2011: Head, Medical Treatment of Gynaecological Neoplasms and Clinical Trials, Gynaecological Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
- 2003 – 2007: Head, Medical Treatment of Gynaecological Neoplasms and Clinical Trials, Gynaecological Oncology Unit, Centro di Ricerca e Formazione ad Alta Tecnologia nelle Scienze Biomediche – Giovanni Paolo II, Campobasso, Italy
- 2003: Training at Trials Unit Clinic, Department of Oncology, “San Giovanni” Hospital, Bellinzona, Switzerland; Breast Unit, MD Anderson Cancer Center, Houston, USA
Prof. Lorusso has managed as principal investigator over 100 phase I, II, III and IV research studies dedicated to gynaecological oncology pathology. She has been an active participant for over 25 years in the clinical research initiatives of cooperative groups dedicated to gynaecological cancers, including MITO, ENGOT, ESMO, ESGO and GCIG, and is still involved in the main initiatives for the development of new drugs in gynaecological oncology. Prof. Lorusso is currently secretary of the MITO group (Multicenter Italian Trials in Ovarian Cancer and Gynecological Malignancies), is an active member of ENGOT (European Network of Gynaecological Oncological Trial groups) and of GCIG (Gynaecological Cancer Intergroup) where she was president of the working group on endometrial cancer and president of the nominations and extraordinary operations committee. She is currently a member of the Board of Directors of GCIG and a member of the Council of the European Society of Gynaecological Oncology (ESGO), as well as a member of the Scientific Committee for Gynaecological Tumours of ESMO (European Society of Medical Oncology). An extender of international, European and national guidelines on the treatment of gynaecological malignancies, he currently coordinates the national working group on ovarian cancer treatment guidelines in the AIOM. Member of the editorial board of several peer-reviewed journals: his selection work helps to promote a high quality of literature in the field for readers and provides authors with a continuous effort to improve their research capabilities. Member of the scientific committee of the Italian Association for Cancer Research, member of the scientific committee of 3 patient advocacy groups: Abracadabra, Acto, Salute Donna. Prof. Lorusso holds research funds for translational clinical activities, obtained from competitive public calls (AIRC and Ricerca Finalizzata Ministeriale).
- Single-Agent Trabectedin Versus Physician’s Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.Lorusso D, Raspagliesi F, Ronzulli D, Valabrega G, Colombo N, Pisano C, Cassani C, Tognon G, Tamberi S, Mangili G, Mammoliti S, De Giorgi U, Greco F, Mosconi AM, Breda E, Artioli G, Andreetta C, Casanova C, Ceccherini R, Frassoldati A, Salutari V, Giolitto S, Scambia G.J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225. Online ahead of print.PMID: 38315944
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups.N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169.PMID: 38055253
- First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Keefe SM, Lorusso D; KEYNOTE-826 Investigators.J Clin Oncol. 2023 Dec 20;41(36):5505-5511. doi: 10.1200/JCO.23.00914. Epub 2023 Nov 1.PMID: 37910822
- Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, Ledermann JA; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.Ann Oncol. 2023 Oct;34(10):833-848. doi: 10.1016/j.annonc.2023.07.011. Epub 2023 Aug 17.PMID: 37597580
- Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.Makker V, Colombo N, Casado Herráez A, Monk BJ, Mackay H, Santin AD, Miller DS, Moore RG, Baron-Hay S, Ray-Coquard I, Ushijima K, Yonemori K, Kim YM, Guerra Alia EM, Sanli UA, Bird S, Orlowski R, McKenzie J, Okpara C, Barresi G, Lorusso D.J Clin Oncol. 2023 Jun 1;41(16):2904-2910. doi: 10.1200/JCO.22.02152. Epub 2023 Apr 14.PMID: 37058687